Programmable patient tissue, without the friction
Embedded Files
We engineer a patient’s own skin cells for the durable production of therapeutic proteins
Recessive Dystrophic Epidermolysis Bullosa
Our first indication is also known as "the butterfly disease" because patients' skin is as fragile as a butterfly's wing
Cause: Defects in COL7A1 lead to a lack of anchoring fibrils that hold layers of skin together.
Pathology: Any friction causes the skin to blister and shear, leading to painful wounds, a 90% increase in skin cancer risk, and early death
Our platform was shown safe and effective in human RDEB patients through an investigator-initiated trial
With competitive advantages in durable efficacy, manufacturing simplicity, and ease of application over all other clinical-stage RDEB therapies, our lean team is excited to bring a best in class option to RDEB patients.
Please reach out to info@addgraft.com to learn more.
Page updated
Report abuse